DM2 is a major comorbidity of COVID-19. It has been observed that subjects with DM2 require more medical interventions, have a significantly higher mortality (7.8% versus 2.7%) and injuries of multiple organs that the individuals not diabetics. In situations of glycemic variability, phenomena of oxidative stress and activation of protein kinase C can be initiated , through the release of pro-inflammatory cytosines , which could induce microvascular damage .Patients with diabetes and COVID-19 were shown to be more likely to develop serious or critical illness with more complications, and to have higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%).
Study Type
OBSERVATIONAL
Enrollment
120
National Institute of Medical Sciences and Nutrition Salvador Zubiran
Mexico City, Mexico
Glucose variability
Percentage of time within the ADA recommended range
Time frame: For up to two weeks, during hospitalization
Insulin use
Average daily UI of insulin per patient
Time frame: For up two weeks, during hospitalization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.